Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Proprotein Convertase Subtilisin & Kexin Type 9 report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Proprotein Convertase Subtilisin & Kexin Type 9 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Cardiovascular Disease and Homozugous Familial Hyperchalesterolemia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Proprotein Convertase Subtilisin & Kexin Type 9 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Proprotein Convertase Subtilisin & Kexin Type 9 key companies include AFFiRiS AG, Betagenon AB, Bioleaders Corp, BioLingus AG, Catabasis Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Eli Lilly and Co, Ensemble Therapeutics Corp and Kowa Co Ltd, etc. AFFiRiS AG, Betagenon AB, Bioleaders Corp are top 3 players and held % share in total in 2022.
Proprotein Convertase Subtilisin & Kexin Type 9 can be divided into SX-PCK9, O-304, K-312 and BLSM-201, etc. SX-PCK9 is the mainstream product in the market, accounting for % share globally in 2022.
Proprotein Convertase Subtilisin & Kexin Type 9 is widely used in various fields, such as Cardiovascular Disease, Homozugous Familial Hyperchalesterolemia, Liver Disease and Metabolic Syndrome, etc. Cardiovascular Disease provides greatest supports to the Proprotein Convertase Subtilisin & Kexin Type 9 industry development. In 2022, global % share of Proprotein Convertase Subtilisin & Kexin Type 9 went into Cardiovascular Disease filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Proprotein Convertase Subtilisin & Kexin Type 9 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
AFFiRiS AG
Betagenon AB
Bioleaders Corp
BioLingus AG
Catabasis Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Ensemble Therapeutics Corp
Kowa Co Ltd
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company
Segment by Type
SX-PCK9
O-304
K-312
BLSM-201
DCRPCSK-9
Others
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Proprotein Convertase Subtilisin & Kexin Type 9 market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Proprotein Convertase Subtilisin & Kexin Type 9 introduction, etc. Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Proprotein Convertase Subtilisin & Kexin Type 9 market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Proprotein Convertase Subtilisin & Kexin Type 9 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Proprotein Convertase Subtilisin & Kexin Type 9 key companies include AFFiRiS AG, Betagenon AB, Bioleaders Corp, BioLingus AG, Catabasis Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Eli Lilly and Co, Ensemble Therapeutics Corp and Kowa Co Ltd, etc. AFFiRiS AG, Betagenon AB, Bioleaders Corp are top 3 players and held % share in total in 2022.
Proprotein Convertase Subtilisin & Kexin Type 9 can be divided into SX-PCK9, O-304, K-312 and BLSM-201, etc. SX-PCK9 is the mainstream product in the market, accounting for % share globally in 2022.
Proprotein Convertase Subtilisin & Kexin Type 9 is widely used in various fields, such as Cardiovascular Disease, Homozugous Familial Hyperchalesterolemia, Liver Disease and Metabolic Syndrome, etc. Cardiovascular Disease provides greatest supports to the Proprotein Convertase Subtilisin & Kexin Type 9 industry development. In 2022, global % share of Proprotein Convertase Subtilisin & Kexin Type 9 went into Cardiovascular Disease filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Proprotein Convertase Subtilisin & Kexin Type 9 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
AFFiRiS AG
Betagenon AB
Bioleaders Corp
BioLingus AG
Catabasis Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Ensemble Therapeutics Corp
Kowa Co Ltd
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company
Segment by Type
SX-PCK9
O-304
K-312
BLSM-201
DCRPCSK-9
Others
Segment by Application
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Proprotein Convertase Subtilisin & Kexin Type 9 market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Proprotein Convertase Subtilisin & Kexin Type 9 introduction, etc. Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Proprotein Convertase Subtilisin & Kexin Type 9 market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices